These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3152810)

  • 21. Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group.
    Thaler J; Hilbe W
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S25-8. PubMed ID: 8769696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of interferon-alpha in treatment of chronic myeloid leukemia].
    Thaler J
    Acta Med Austriaca; 1993; 20(3):65-9. PubMed ID: 8368048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on therapeutic options for chronic myelogenous leukemia.
    Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):31-6. PubMed ID: 2197731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
    Sacchi S; Cortes J; Kantarjian H; Talpaz M
    Hematopathol Mol Hematol; 1997-1998; 11(1):41-7. PubMed ID: 9439979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons].
    Cazzola M; Pedrazzoli P; Bergamaschi G; Buonanno C; Cuomo A; D'Uva R; Ponchio L; Rosti V; Zappone E; Ascari E
    Haematologica; 1990; 75 Suppl 4():20-7. PubMed ID: 2127411
    [No Abstract]   [Full Text] [Related]  

  • 27. [Chronic myelogenous leukemia].
    Ohnishi K
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
    Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
    Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD;
    Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia.
    Habermann TM
    Oncol Nurs Forum; 1989; 16(6 Suppl):8-11. PubMed ID: 2687814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [One-year remission of chronic myelogenous leukemia (CML) after discontinuation of interferon-alpha].
    Kobayashi Y; Kimura S; Tanaka K; Kimura S; Wada K; Ozawa M; Maruo N; Kondo M
    Rinsho Ketsueki; 1990 Jul; 31(7):1013-6. PubMed ID: 2214181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
    O'Brien S; Witt R; Talpaz M; Kantarjian H
    Cancer; 1991 Apr; 67(7):1946-9. PubMed ID: 2004308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
    Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():63. PubMed ID: 2496883
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiac arrhythmia in a CML patient treated with interferons.
    Lee KH; Gutterman JU; Ali MK; Talpaz M
    Tex Med; 1989 Apr; 85(4):36-8. PubMed ID: 2499075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
    Nolte KU; Günther G; von Wussow P
    Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
    Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
    Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of interferons in the treatment of hematologic malignancies.
    Gutterman JU
    Semin Hematol; 1988 Jul; 25(3 Suppl 3):3-8. PubMed ID: 2459780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.